# A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

> **NCT00139789** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 60 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Kemstro

## Key facts

- **NCT ID:** NCT00139789
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00139789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00139789, "A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00139789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*